216 related articles for article (PubMed ID: 22901442)
21. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
[TBL] [Abstract][Full Text] [Related]
22. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Orphanos G; Alexopoulos A; Malliou S; Ioannidis G; Ardavanis A; Kandylis C; Stavrakakis J; Rigatos G
J Cancer Res Clin Oncol; 2010 Jan; 136(1):115-21. PubMed ID: 19672628
[TBL] [Abstract][Full Text] [Related]
23. A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer.
Xu HB; Xu Q; Li L
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1005-13. PubMed ID: 21170550
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of doublet versus single agent as salvage treatment for metastatic breast cancer pretreated with anthracyclines and taxanes: a systematic review and meta-analysis.
Zhang T; Wang R; Liu Y; Huang J; Yang Z
Curr Med Res Opin; 2016 Nov; 32(11):1883-1889. PubMed ID: 27489049
[TBL] [Abstract][Full Text] [Related]
25. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
28. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
Jiang Z; Yang Y; Li L; Yue Z; Lan L; Pan Z
J Cancer Res Ther; 2018 Dec; 14(Supplement):S957-S963. PubMed ID: 30539829
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
31. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Baselga J; Zamagni C; Gómez P; Bermejo B; Nagai SE; Melichar B; Chan A; Mángel L; Bergh J; Costa F; Gómez HL; Gradishar WJ; Hudis CA; Rapoport BL; Roché H; Maeda P; Huang L; Meinhardt G; Zhang J; Schwartzberg LS
Clin Breast Cancer; 2017 Dec; 17(8):585-594.e4. PubMed ID: 28830796
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Malmström A; Hansen J; Malmberg L; Carlsson L; Svensson JH; Ahlgren J; Ahlin C; Jansson T; Westberg R
Acta Oncol; 2010; 49(1):35-41. PubMed ID: 19839920
[TBL] [Abstract][Full Text] [Related]
33. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G
Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
[TBL] [Abstract][Full Text] [Related]
36. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
37. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Gómez HL; Neciosup S; Tosello C; Mano M; Bines J; Ismael G; Santi PX; Pinczowski H; Nerón Y; Fanelli M; Fein L; Sampaio C; Lerzo G; Capó A; Zarba JJ; Blajman C; Varela MS; Martínez-Mesa J; Werutsky G; Barrios CH
Clin Breast Cancer; 2016 Feb; 16(1):38-44. PubMed ID: 26642810
[TBL] [Abstract][Full Text] [Related]
38. A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Seidman AD; Chan S; Wang J; Zhu C; Xu C; Xu B
Oncologist; 2014 May; 19(5):443-52. PubMed ID: 24705980
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SH; Lee J; Park J; Park SH; Lee KE; Lee SI; Nam E; Park JO; Kim K; Jung CW; Park YS; Yoon SS; Kang WK; Lee MH; Park K; Im YH
Med Oncol; 2004; 21(3):223-31. PubMed ID: 15456949
[TBL] [Abstract][Full Text] [Related]
40. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
